The new angiotensin II receptor blocker Edarbi® as part of the pathogenetic treatment of arterial hypertension in patients with metabolic disorders

The new angiotensin II receptor blocker Edarbi® as part of the pathogenetic treatment of arterial hypertension in patients with metabolic disorders

Relevance. Recently, the proportion of angiotensin receptor blockers has significantly increased among prescribed antihypertensive drugs. High organoprotective properties, additional metabolic effects and tolerability comparable to placebo make them the drugs of choice, especially in patients with s...

Full description

Bibliographic Details
Main Authors: Chazova I.Ye., Zhernakova Yu.V., Blinova N.V., Rogoza A.N.
Format: Article
Language:Russian
Published: IP Morozov P.V. 2017-09-01
Series:Системные гипертензии
Subjects:
arterial hypertension
metabolic syndrome
antihypertensive therapy
target organs
Online Access:http://syst-hypertension.ru/en/archive/2017/vol-14-3-2017/the-new-angiotensin-ii-receptor-blocker-edarbi-as-part-of-the-pathogenetic-treatment-of-arterial-hyp_1813/

Internet

http://syst-hypertension.ru/en/archive/2017/vol-14-3-2017/the-new-angiotensin-ii-receptor-blocker-edarbi-as-part-of-the-pathogenetic-treatment-of-arterial-hyp_1813/

Similar Items